QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: PASS in the EU Risk Management Plan

Test your understanding of the concepts covered by GVP Module VIII: PASS in the Risk Management Plan.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the key difference between assessing implementation of a risk-minimisation measure and assessing its effectiveness?

Implementation concerns whether the measure was delivered or followed; effectiveness concerns whether it achieved the intended behavioural or clinical outcome. Implementation is a scientific assessment, whereas effectiveness is only an administrative assessment. Implementation always proves effectiveness if the communication was received. Effectiveness can be assessed without defining the intended risk-reduction objective.

Question 2 of 10 What is the appropriate basis for deciding whether a missing-information concern has been reduced by a PASS?

Whether the planned sample size was reached, regardless of what was learned. Whether the study generated evidence adequate in population, duration, exposure and outcome ascertainment to address the original limitation. Whether the study was completed within the original project timeline. Whether the study produced a statistically significant finding.

Question 3 of 10 When might a PASS appropriately be removed or reconsidered in the pharmacovigilance plan?

Whenever the study is overdue, regardless of its scientific purpose. When another source adequately answers the question, the concern is no longer relevant or the study is unlikely to achieve its stated purpose, subject to regulatory considerations. Only after the product has been withdrawn. Whenever the study produces an inconclusive result.

Question 4 of 10 A PASS is completed and the final report is available. What is the most appropriate next governance step?

Automatically remove the study from all RMP documentation. Automatically reclassify the investigated risk as resolved. Perform a scientific impact assessment covering the safety specification, pharmacovigilance plan and relevant risk-minimisation measures. Wait until the next routine RMP cycle before reviewing the results.

Question 5 of 10 Which statement best describes the relationship between a PASS and the RMP?

The PASS is the complete risk-management strategy for the medicinal product. The PASS generates evidence as one activity within the broader risk-management system described by the RMP. The RMP is a study protocol that determines how the PASS must be conducted. The PASS replaces the safety specification once the study has started.

Question 6 of 10 How should PASS evidence generally relate to the PSUR?

The PSUR should ignore the study because the RMP is the only downstream interface. The PSUR should reproduce the PASS report without performing its own cumulative evaluation. Relevant study progress, results or implications should enter the appropriate aggregate reporting process and be evaluated for the PSUR's purpose. The PSUR should replace the need for a final PASS report.

Question 7 of 10 For an imposed non-interventional PASS, why may a substantial amendment require specific regulatory handling in addition to internal protocol change control?

Because every voluntary study is legally prohibited from amendment. Because the imposed study has a regulatory basis and applicable procedures may control substantial changes to the agreed activity. Because the RMP cannot be updated after study initiation. Because non-interventional studies do not require protocols.

Question 8 of 10 Which proposed PASS objective has the clearest and most useful relationship to an RMP concern?

To conduct further safety monitoring of the product. To collect all available information about the medicine. To estimate the incidence of a defined outcome in a population for which important epidemiological information is missing. To analyse a database because it contains a large number of exposed patients.

Question 9 of 10 Which sequence most accurately represents the evidence-to-decision chain described in the article?

PASS result, safety concern, protocol, RMP decision, safety specification. Safety concern or knowledge gap, pharmacovigilance objective, PASS, evidence, updated safety assessment, RMP decision. RMP decision, PASS, safety concern, routine pharmacovigilance, protocol. Risk-minimisation measure, final report, safety specification, study objective, signal detection.

Question 10 of 10 An inspector asks why a PASS is listed in the RMP, but the organisation cannot identify the safety concern or knowledge gap it addresses. What does this most strongly suggest?

The study is automatically invalid because its final report is unavailable. The RMP entry may have become an administrative listing rather than a meaningful representation of the pharmacovigilance strategy. The study must be a voluntary study rather than an imposed study. The safety specification is necessarily incorrect.

Knowledge Assessment: PASS in the EU Risk Management Plan

Cookie Settings